|
US745168A
(en)
|
1903-07-16 |
1903-11-24 |
Arthur C Eastwood |
System for control of electric motors.
|
|
US6087380A
(en)
|
1949-11-24 |
2000-07-11 |
Boehringer Ingelheim Pharma Kg |
Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
|
|
EP0198395A3
(en)
|
1985-04-09 |
1989-04-12 |
Mitsubishi Kasei Corporation |
Separating agent for mixed solution
|
|
US4847092A
(en)
|
1985-11-12 |
1989-07-11 |
Eli Lilly And Company |
Orally administerable sustained release pharmaceutical formulations
|
|
DE59808063D1
(de)
|
1998-06-03 |
2003-05-28 |
Gergely Dr & Co |
Mit Alkali- bzw. Erdalkali-Ionen dotierte Zitronensäure
|
|
JP2000309588A
(ja)
|
1999-04-28 |
2000-11-07 |
Taisho Pharmaceut Co Ltd |
固体分散体
|
|
EA003052B1
(ru)
|
1999-07-27 |
2002-12-26 |
Балканфарма Холдинг АД |
Антиаритмическое лекарственное средство
|
|
JP2003523358A
(ja)
|
2000-01-27 |
2003-08-05 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
神経変性疾患の治療のためのピリドピリミジノン誘導体
|
|
US7022711B2
(en)
|
2000-08-04 |
2006-04-04 |
Warner-Lambert Company |
2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
|
|
WO2003024426A1
(en)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Controlled release solid dispersions
|
|
MXPA04005939A
(es)
|
2002-01-22 |
2005-01-25 |
Warner Lambert Co |
2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
|
|
CA2476054C
(en)
|
2002-03-07 |
2011-11-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
|
|
US20030181488A1
(en)
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
|
|
DE10209985A1
(de)
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma |
Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
|
|
US7884127B2
(en)
|
2002-07-08 |
2011-02-08 |
Pirimal Life Sciences Ltd. |
Inhibitors of cyclin dependent kinases and their use
|
|
AU2004255934B2
(en)
|
2003-07-11 |
2010-02-25 |
Warner-Lambert Company Llc |
Isethionate salt of a selective CDK4 inhibitor
|
|
GB0317663D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
|
DE10339862A1
(de)
|
2003-08-29 |
2005-03-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
|
|
DE102004062864A1
(de)
|
2004-12-21 |
2006-06-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Folienbehälter
|
|
KR101313702B1
(ko)
|
2005-02-03 |
2013-10-04 |
와이어쓰 |
제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
|
|
KR100678824B1
(ko)
*
|
2005-02-04 |
2007-02-05 |
한미약품 주식회사 |
용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
|
|
KR100627687B1
(ko)
|
2005-04-20 |
2006-09-25 |
주식회사 씨티씨바이오 |
시부트라민 유리염기 함유 조성물 및 이의 제조방법
|
|
WO2006112649A1
(en)
|
2005-04-20 |
2006-10-26 |
Ctc Bio, Inc. |
Pharmaceutical composition containing sibutramine free base and manufacturing method thereof
|
|
EP1919460A2
(en)
|
2005-08-22 |
2008-05-14 |
Novartis AG |
Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
|
|
KR20140088230A
(ko)
|
2006-01-27 |
2014-07-09 |
앱탈리스 파마테크, 인코포레이티드 |
약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
|
|
US20090030005A1
(en)
|
2007-07-19 |
2009-01-29 |
Amgen Inc. |
Combinations for the treatment of cancer
|
|
EP2200613B1
(en)
|
2007-09-21 |
2018-09-05 |
The Johns Hopkins University |
Phenazine derivatives and uses thereof
|
|
WO2009061345A2
(en)
|
2007-11-07 |
2009-05-14 |
Cornell Research Foundation, Inc. |
Targeting cdk4 and cdk6 in cancer therapy
|
|
JP2012504646A
(ja)
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
WO2010055119A2
(en)
|
2008-11-17 |
2010-05-20 |
Novartis Ag |
Pharmaceutical composition comprising pimobendan
|
|
DE102009028354B4
(de)
|
2009-08-07 |
2013-05-29 |
Mtu Friedrichshafen Gmbh |
Gasführungssystem für eine Peripherie einer Brennkraftmaschine zur Führung von Gas der Brennkraftmaschine, Brennkraftsystem und Verfahren zum Betrieb der Brennkraftmaschine
|
|
EP2502078A1
(en)
|
2009-11-20 |
2012-09-26 |
Infinity Pharmaceuticals, Inc. |
Methods and compositions for treating hedgehog-associated cancers
|
|
CN102106807B
(zh)
|
2009-12-29 |
2013-03-27 |
上海中西制药有限公司 |
一种固体制剂的制备方法及所得固体制剂
|
|
CN102106806B
(zh)
|
2009-12-29 |
2013-04-17 |
上海中西制药有限公司 |
一种固体制剂的制备方法及所得固体制剂
|
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
BR112012031516A2
(pt)
|
2010-06-09 |
2016-11-08 |
Abbott Lab |
dispersões sólidas contendo inibidores de quinase
|
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
|
SI2782557T1
(sl)
|
2011-11-23 |
2019-02-28 |
Array Biopharma, Inc., |
Farmacevtske formulacije
|
|
EP2870261B1
(en)
|
2012-07-09 |
2017-12-06 |
Novartis AG |
Biomarkers associated with cdk inhibitors
|
|
WO2014121235A2
(en)
|
2013-02-01 |
2014-08-07 |
Zoneone Pharma, Inc. |
Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
|
|
MX386473B
(es)
|
2013-02-21 |
2025-03-18 |
Pfizer |
Formas solidas de un inhibidor de cdk4/6 selectivo
|
|
AU2014253932B2
(en)
|
2013-04-16 |
2020-04-30 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for CDK4 inhibitors
|
|
CN111012756B
(zh)
|
2013-06-21 |
2023-06-13 |
四川海思科制药有限公司 |
一种达比加群酯药物组合物及其制备方法
|
|
CN105828822B
(zh)
|
2013-08-14 |
2019-10-18 |
诺华股份有限公司 |
用于治疗癌症的组合疗法
|
|
AU2014348657A1
(en)
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
|
US20170067116A1
(en)
|
2014-03-04 |
2017-03-09 |
The Regents Of The University Of California |
Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in Cancer
|
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
PL3154512T3
(pl)
|
2014-05-01 |
2019-12-31 |
Hermes Arzneimittel Gmbh |
Stałe preparaty do podawania doustnego zawierające stałe stopione dyspersje kwasów organicznych w ksylitolu
|
|
CN105294682B
(zh)
|
2014-07-26 |
2017-07-07 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
CN105616418A
(zh)
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
CN105616419A
(zh)
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
|
|
CN104434809B
(zh)
|
2014-12-10 |
2018-10-16 |
北京科莱博医药开发有限责任公司 |
一种奥拉帕尼固体分散体制剂及其制备方法
|
|
SI3255046T1
(sl)
|
2015-02-03 |
2020-02-28 |
Jiangsu Hengrui Medicine Co., Ltd. |
Hidroksietil sulfonat zaviralca od ciklina odvisne protein-kinaze, njegova kristalinična oblika in postopek priprave le-teh
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN104887641B
(zh)
|
2015-04-08 |
2017-12-01 |
上海鲁源医药科技有限公司 |
帕布昔利布胃漂浮片及其制备方法
|
|
KR102369405B1
(ko)
|
2015-06-04 |
2022-03-02 |
화이자 인코포레이티드 |
팔보시클립의 고체 투여 형태
|
|
CN105085517B
(zh)
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
WO2017036390A1
(zh)
|
2015-09-01 |
2017-03-09 |
上海方楠生物科技有限公司 |
帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
|
|
CN106474129A
(zh)
|
2015-09-01 |
2017-03-08 |
上海方楠生物科技有限公司 |
一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
|
|
CN107510847A
(zh)
|
2016-06-16 |
2017-12-26 |
常州方楠医药技术有限公司 |
一种含有无定型帕博西林固体分散体的药用组合物及其制备方法
|
|
CN105213322A
(zh)
|
2015-10-30 |
2016-01-06 |
南京正大天晴制药有限公司 |
一种干法制粒工艺制备的药物组合物
|
|
CN106831710A
(zh)
|
2015-12-07 |
2017-06-13 |
常州爱诺新睿医药技术有限公司 |
一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
|
|
WO2017115315A1
(en)
|
2015-12-30 |
2017-07-06 |
Dr. Reddy's Laboratories Limited |
Solid forms of palbociclib
|
|
CN106967061A
(zh)
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
|
WO2017130219A1
(en)
*
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
AU2017235450A1
(en)
|
2016-03-15 |
2018-08-16 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
|
|
US10690673B2
(en)
|
2016-03-29 |
2020-06-23 |
Mayo Foundation For Medical Education And Research |
Method of treating cancer metastasis by CDK 4/6 inhibitors
|
|
CN105816437B
(zh)
|
2016-03-29 |
2018-08-03 |
深圳市药欣生物科技有限公司 |
一种帕布昔利布的药物制剂及其制备方法
|
|
CN105748435B
(zh)
|
2016-04-21 |
2019-03-29 |
石家庄海瑞药物科技有限公司 |
一种帕布昔利布药物组合物及其制备方法
|
|
US20190345558A1
(en)
|
2016-05-18 |
2019-11-14 |
Université Libre de Bruxelles |
Method for determining sensitivity to a cdk4/6 inhibitor
|
|
EP3255048A1
(en)
|
2016-06-07 |
2017-12-13 |
K.H.S. Pharma Holding GmbH |
Non-crystalline form of palbociclib
|
|
ES2909576T3
(es)
|
2016-10-11 |
2022-05-09 |
Univ Duke |
Tratamiento con lasofoxifeno del cáncer de mama ER+
|
|
CN108017629A
(zh)
|
2016-11-04 |
2018-05-11 |
上海奥博生物医药技术有限公司 |
一种帕博西尼无定形态
|
|
CN106667952A
(zh)
|
2016-12-12 |
2017-05-17 |
河南润弘制药股份有限公司 |
一种帕布昔利布药物组合物及其制备方法
|
|
WO2018134843A1
(en)
*
|
2017-01-23 |
2018-07-26 |
Msn Laboratories Private Limited, R&D Center |
Polymorphic forms of (e)-n-{4-[3-chloro-4-((pyridin-2-yl methoxy)anilino]-3-cyano-7- ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, its maleate salt and process for preparation thereof
|
|
CN110573183A
(zh)
|
2017-04-21 |
2019-12-13 |
上海方楠生物科技有限公司 |
一种帕博西林组合物及其制备方法
|
|
CN108864078B
(zh)
|
2017-05-10 |
2021-10-15 |
江苏豪森药业集团有限公司 |
帕博西尼晶型b的制备方法
|
|
WO2019056163A1
(zh)
|
2017-09-19 |
2019-03-28 |
浙江华海药业股份有限公司 |
N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
|
|
CN108014343A
(zh)
|
2017-12-21 |
2018-05-11 |
孟斯琴 |
一种治疗乳腺癌的药物组合物及其制备方法
|
|
CN108066312B
(zh)
|
2017-12-29 |
2020-03-20 |
山东裕欣药业有限公司 |
一种帕博西尼药物组合物及其制备方法
|
|
CN108066303A
(zh)
|
2017-12-31 |
2018-05-25 |
湖南博隽生物医药有限公司 |
一种抗癌药物组合物及其制备方法
|
|
WO2019178239A1
(en)
|
2018-03-13 |
2019-09-19 |
Board Of Regents, The University Of Texas System |
Methods for treatment of cancers with egfr activating mutations
|
|
CN108272754A
(zh)
|
2018-04-11 |
2018-07-13 |
吴小戈 |
一种抗癌药物固体分散体组合物及其制备方法
|
|
EP4309656A3
(en)
|
2018-05-14 |
2024-02-28 |
Pfizer Inc. |
Oral solution formulation
|
|
CN108653222A
(zh)
|
2018-07-03 |
2018-10-16 |
威海贯标信息科技有限公司 |
一种帕博西尼片剂组合物
|